Imaoka Hiroshi, Sasaki Mitsuhito, Hashimoto Yusuke, Watanabe Kazuo, Ikeda Masafumi
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
J Clin Med. 2019 Aug 5;8(8):1173. doi: 10.3390/jcm8081173.
Pancreatic cancer is a lethal cancer with an increasing incidence. Despite improvements in chemotherapy, patients with pancreatic cancer continue to face poor prognoses. Endoscopic ultrasound-guided tissue acquisition (EUS-TA) is the primary method for obtaining tissue samples of pancreatic cancer. Due to advancements in next-generation sequencing (NGS) technologies, multiple parallel sequencing can be applied to EUS-TA samples. Genomic biomarkers for therapeutic stratification in pancreatic cancer are still lacking, however, NGS can unveil potential predictive genomic biomarkers of treatment response. Thus, the importance of NGS using EUS-TA samples is becoming recognized. In this review, we discuss the recent advances in EUS-TA application for NGS of pancreatic cancer.
胰腺癌是一种发病率不断上升的致命癌症。尽管化疗有所改善，但胰腺癌患者的预后仍然很差。内镜超声引导下组织获取（EUS-TA）是获取胰腺癌组织样本的主要方法。由于下一代测序（NGS）技术的进步，多重平行测序可应用于EUS-TA样本。然而，胰腺癌治疗分层的基因组生物标志物仍然缺乏，NGS可以揭示治疗反应的潜在预测性基因组生物标志物。因此，使用EUS-TA样本进行NGS的重要性正逐渐得到认可。在这篇综述中，我们讨论了EUS-TA在胰腺癌NGS应用方面的最新进展。
